Hypercholesterolemia Presenting in a Patient with Familial Defective Apolipoprotein B-100 and Hypothyroidism

Brown MS Goldstein JL . A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34–47.

Walton KW Scott PJ Dykes PW Davies JWL . The significance of alterations in serum lipids in thyroid dysfunction. II Alterations of the metabolism and turnover of ¹³¹I-low density lipoproteins in hypothyroidism and thyrotoxicosis. Clin Sci 1965; 29: 984–94.

Thompson GR Soutar AK Spengel FA Jadhav A Gavigan S Myant NB . Defects of the receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolaemia and hypothyroidism in vivo. Proc Nat Acad Sci USA 1981; 78: 2591–5.

Myant NB . Cholesterol Metabolism, LDL, and the LDL-Receptor. London: Academic Press Inc; 1990.

Innerarity TL Mahley RW Weisgraber KH Bersot TP Krauss RM Vega GL Familial defective apolipoprotein B-100: A mutation of apolipoprotein B that causes hypercholesterolaemia. J Lipid Res 1990; 31: 1337–49.

Myant NB . Familial defective apolipoprotein B-100: A review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993; 104: 1–18.

Friedwald WT Levy RI Frederickson DS . Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

Miller SA Dykes DD Polesky HF . A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.

Hansen PS Rüdiger N Tybjærg-Hansen A Færgeman O Gregersen N. Detection of the apo B-3500 mutation (glutamine for arginine) by gene amplification and cleavage with MspI. J Lipid Res 1991; 32: 1229–33.

Motti C Funke H Rust S Dergunov A Assman G. Using mutagenic polymerase chain reaction primers to detect carriers of familial defective apolipoprotein B-100. Clin Chem 1991; 37: 1762–6.

Corsini A Mazzotti M Fumagalli R Catapano AL Romano L Romano C. Poor response to simvastatin in familial defective apo-B-100. Lancet 1991; 337: 305.

Maher VMG Gallagher JJ Thompson GR Myant NB . Response to cholesterol-lowering drugs in familial defective apolipoprotein B-100. Atherosclerosis 1991; 91: 73–6.

Illingworth DR Vakar F Mahley RW Weisgraber KH . Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100. Lancet 1992; 339: 598–600.

Schmidt EB Illingworth DR Bacon S Mahley RW Weisgraber KH . Hypocholesterolaemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100. Atherosclerosis 1993; 98: 213–17.

Caron P Calazel C Parra HJ Hoff M Louvet JP . Decreased HDL cholesterol in subclinical hypothyroidism: The effect of L-thyroxine therapy. Clin Endocrinol 1990; 33: 519–23.

Parle JV Franklyn JA Cross KW Jones SR Sheppard MC . Circulating lipids and minor abnormalities of thyroid function. Clin Endocrinol 1992; 37: 411–14.

Powell JT Carter G Woolcock N Greenhalgh RM Fowler PBS Zadej J. Alaghband . The relationship between serum cholesterol and serum thyrotropin in women with peripheral arterial disease. Ann Clin Biochem 1991; 28: 318–19.

Toft AD Campbell IW Seth J. Diagnosis and Management of Endocrine Diseases. Edinburgh: Blackwell, 1981: 179.